Abstract
This is a summary of the original article ‟Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis”. DMO, a serious eye condition that can lead to vision loss in people with diabetes, is a significant health concern and a lack of knowledge exists about the cost-effectiveness (the balance of a treatment’s cost and its effectiveness) of new treatments. This research assessed the cost-effectiveness of a new medication named faricimab, using a mathematical model that simulated the progression of DMO and its treatment over 25 years. The model compared faricimab against relevant therapeutic alternatives for DMO in the UK, including ranibizumab, aflibercept, and bevacizumab. The research discovered that faricimab could offer improved vision results and be cost saving or cost-effective. It also suggested that faricimab could lessen the strain on healthcare services due to its less frequent dosing schedule. Overall, such findings suggest that faricimab is a promising new treatment option for DMO that could benefit patients and the healthcare system. This could have implications for future treatment guidelines and the management of DMO in clinical practice.
Keywords: Cost-effectiveness analysis, Diabetic macular oedema, Faricimab
Summary of Research
This is a summary of the original article: “Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis” [1].
Acknowledgements
Medical Writing/Editorial Assistance
This summary was developed by Steve Winter, Keith Evans, and Simon Rowlands of inScience Communications, a part of Springer Healthcare/Springer Nature Group, including the use of currently available AI platforms (April 2024). The output generated by such AI systems has undergone human intervention by professional inScience Communications staff for accuracy and quality assurance purposes. Medical writing support was funded by F. Hoffmann-La Roche Limited, Basel, Switzerland.
Author Contributions
Christian Bührer, Thomas Paling, Richard Gale, Tatiana Paulo, and Marloes Bagijn all agreed to the development and submission of this Summary of Research article and approved the final version for publication.
Funding
This analysis and this summary of the study results were funded by F. Hoffmann-La Roche Limited, Basel, Switzerland. The sponsor also funded the journal’s Rapid Service Fee.
Data Availability
All data used for the cost-effectiveness model are provided in the original article or are publicly available as indicated by citations. The cost-effectiveness model was developed in Microsoft Excel 365 (Microsoft Corporation). Additional information about model programming is available from the corresponding author upon request.
Declarations
Conflict of Interest
Please see the original article for full author disclosures.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Please see the referenced article for ethics relating to the original study.
Reference
- 1.Bührer C, Paling T, Gale R, Paulo T, Bagijn M. Cost-effectiveness of faricimab in the treatment of diabetic macular oedema (DMO): a UK analysis. PharmacoEcon Open. 2024;8(3):445–457. doi: 10.1007/s41669-023-00465-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data used for the cost-effectiveness model are provided in the original article or are publicly available as indicated by citations. The cost-effectiveness model was developed in Microsoft Excel 365 (Microsoft Corporation). Additional information about model programming is available from the corresponding author upon request.